Half-Year 2022 Financial and Clinical Trials Update

Kadcyla CER growth -1% Europe +10% Global sales CHFbn CER growth +14% Regional sales 1.2 US 1.0 0.8 0.6 0.4 0.2 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,074m • US: Growth in adjuvant eBC; share decline in metastatic BC due to competition • . EU: Strong uptake in adjuvant eBC in patients with residual disease after neoadjuvant treatment International: Growth driven by all regions CER=Constant Exchange Rates Japan +23% International +52% Roche 178

View entire presentation